News
CORT ▼ -1.0% - Corcept Therapeutics Incorporated
CORT ▼ -1.0% - Corcept Therapeutics Incorporated
$CORT Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
26-OCT-2026 08:03 AM ET
Share this post
More filings for $CORT
CORT ▼ -1.0% - Corcept Therapeutics IncorporatedOct 26, 2026CORT ▼ -13.2% - Corcept Therapeutics IncorporatedOct 23, 2026CORT ▲ +3.9% - Corcept Therapeutics IncorporatedOct 20, 2026CORT ▲ +0.0% - Corcept Therapeutics IncorporatedSep 23, 2026CORT ▼ -0.1% - Corcept Therapeutics IncorporatedSep 18, 2026
View full $CORT filing history →💬 Comments
Loading comments…
Leave a comment